NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study That Will Evaluate the Brazilian Population With COPD.

RecruitingN/A

Sponsor: AstraZeneca

Conditions: COPD (Chronic Obstructive Pulmonary Disease)

Countries: Brazil

Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT \>=10); or
* GOLD E (\>=2 moderate or 1 severe exacerbation - hospitalization); or
* GOLD 3 and 4 (FEV1 \<50%).

Exclusion Criteria:

* Advanced fibrosing interstitial lung disease (extent \>=50%); and/or
* High-risk pulmonary hypertension (on triple therapy); and/or
* Active cancer - on systemic therapy

Locations (10)

Aparecida de Goiânia, Brazil
Bahia, Brazil
Belém, Brazil
Brasília, Brazil
Campo Grande, Brazil
Florianópolis, Brazil
Goiânia, Brazil
Santo André, Brazil
São Paulo, Brazil
Uberlândia, Brazil